Basic Information
| LncRNA/CircRNA Name | LINC00485 |
| Synonyms | NA |
| Region | GRCh38_12:102809280-102824399 |
| Ensemble | ENSG00000258169 |
| Refseq | NR_033855 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, western blot |
| Sample | LAC cell line |
| Expression Pattern | up-regulated |
| Function Description | LINC00485 acted as a competitive endogenous RNA against miR-195, and miR-195 directly targeted CHEK1. The expression of LINC00485 was higher in LAC cells. |
| Pubmed ID | 31528122 |
| Year | 2019 |
| Title | Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to regulate the chemotherapy sensitivity of lung adenocarcinoma cells to cisplatin by regulating CHEK1. |
External Links
| Links for LINC00485 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |